The hydroxymethyl glutaryl coenzyme A reductase inhibitors or statins offer important benefits for the large populations of individuals at high risk for coronary heart disease. These drugs have a good safety profile. Nevertheless, differences in physicochemical and pharmacokinetic properties between statins may translate into significant differences in long-term safety. This review focuses on long-term adverse effects related to statin use, namely hepatotoxicity and myopathy. Moreover, the most common drugs used in combination with statins in long-term therapies are analyzed in terms of possible drug/drug interactions affecting the safety of statins.
Safety considerations for statins / C. Bolego, R. Baetta, S. Bellosta, A. Corsini, R. Paoletti. - In: CURRENT OPINION IN LIPIDOLOGY. - ISSN 0957-9672. - 13:6(2002 Dec), pp. 637-644.
Safety considerations for statins
C. BolegoPrimo
;R. BaettaSecondo
;S. Bellosta;A. CorsiniPenultimo
;R. PaolettiUltimo
2002
Abstract
The hydroxymethyl glutaryl coenzyme A reductase inhibitors or statins offer important benefits for the large populations of individuals at high risk for coronary heart disease. These drugs have a good safety profile. Nevertheless, differences in physicochemical and pharmacokinetic properties between statins may translate into significant differences in long-term safety. This review focuses on long-term adverse effects related to statin use, namely hepatotoxicity and myopathy. Moreover, the most common drugs used in combination with statins in long-term therapies are analyzed in terms of possible drug/drug interactions affecting the safety of statins.File | Dimensione | Formato | |
---|---|---|---|
2002 Curr Opin Lipidol Safety considerations.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
90.27 kB
Formato
Adobe PDF
|
90.27 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.